What enclomiphene is
Enclomiphene is the trans-isomer of clomiphene citrate. Originally clomiphene was used in women for ovulation induction. Researchers later identified that the two isomers (enclomiphene = trans, zuclomiphene = cis) have different properties, enclomiphene is the active testosterone-raising component without the estrogen-like effects of zuclomiphene.
Mechanism, fertility-preserving
The hypothalamus monitors blood estrogen levels. When estrogen feedback signals are blocked at hypothalamic estrogen receptors (which is what enclomiphene does), the brain "thinks" estrogen is low and signals the pituitary to produce more LH and FSH. LH stimulates Leydig cells to produce testosterone. FSH stimulates Sertoli cells to support spermatogenesis.
The key difference from traditional TRT: testosterone rises from the testicles (endogenous production), not from injected exogenous hormone. This means:
- The HPG axis stays online
- Testicular volume preserved
- Sperm production maintained or improved
- Reversible, stop the medication and the system returns to baseline
Enclomiphene vs clomiphene
Clomiphene (the racemic mixture of trans- and cis-isomers) is the older, more widely available drug. It works for the same purpose but contains the cis-isomer (zuclomiphene), which has long-acting estrogenic effects that contribute to side effects (visual changes, mood issues) more than enclomiphene alone. Enclomiphene gives you the testosterone-raising benefit with fewer of the issues.
Fertility-specific data
The Hill et al. and Wiehle et al. trials showed enclomiphene in hypogonadal men:
- Total T rose from baseline ~270 ng/dL to ~600-800 ng/dL
- LH and FSH increased physiologically
- Sperm count maintained or improved (vs. suppression on TRT)
- Effect plateaus around 12 weeks
Enclomiphene vs traditional TRT
| Factor | Enclomiphene | Standard TRT |
|---|---|---|
| T elevation | +250-500 ng/dL | +400-800 ng/dL |
| Fertility | Preserved or improved | Suppressed without HCG add-on |
| HPG axis | Preserved | Suppressed |
| Testicular volume | Maintained | Decreases without HCG |
| Reversibility | Days-weeks | Months (restart protocol) |
| Administration | Daily oral pill | Weekly/twice-weekly injection |
| Indication | Secondary hypogonadism | Primary or secondary |
Dosing
- Standard starting dose: 12.5 mg daily, oral
- Common range: 12.5-25 mg daily
- Take in the morning consistently
- Re-test labs at 6-8 weeks, total T, free T, LH, FSH, estradiol
- Adjust dose based on response
Side effects
- Visual changes (rare, usually transient, but require evaluation if persistent)
- Hot flashes or mood changes (less common with enclomiphene than clomiphene)
- Headaches (mild)
- Mild GI symptoms
- Estradiol may rise, monitor sensitive E2
Side effects are generally well-tolerated. Most patients have minimal complaints.
Who it's right for
- Men with secondary hypogonadism (low T, low/normal LH/FSH)
- Men actively trying to conceive or planning future fertility
- Men with testicular atrophy on prior TRT wanting to restart natural production
- Younger men (under 40) with reversible drivers of low T
- Men preferring oral medication over injections
Not appropriate for: primary hypogonadism (testes can't respond), men with active prostate cancer or pituitary tumors, men with significant baseline estradiol concerns.
The clinical pearl: Enclomiphene fills a real niche, testosterone elevation with preserved fertility. For young men with secondary hypogonadism wanting kids in the future, it's often the right starting point before considering TRT.
Bottom line
Enclomiphene works through endogenous stimulation rather than exogenous replacement. For men with secondary hypogonadism, especially those wanting fertility, it's a legitimate alternative to TRT with substantial preservation benefits. The trade-off is slightly smaller T elevation than full TRT, usually a worthwhile trade for the fertility preservation.